Cover Image

The potential of natural products to inhibit abnormal aggregation of α-Synuclein in the treatment of Parkinson's disease

Parkinson's disease (PD), as a refractory neurological disorder with complex etiology, currently lacks effective therapeutic agents. Natural products (NPs), derived from plants, animals, or microbes, have shown promising effects in PD models through their antioxidative and anti-inflammatory pro...

Full description

Saved in:

Bibliographic Details
Main Authors:	Kaixia Yang (Author), Zhongyue Lv (Author), Wen Zhao (Author), Guogang Lai (Author), Cheng Zheng (Author), Feiteng Qi (Author), Cui Zhao (Author), Kaikai Hu (Author), Xiao Chen (Author), Fan Fu (Author), Jiayi Li (Author), Guomin Xie (Author), Haifeng Wang (Author), Xiping Wu (Author), Wu Zheng (Author)
Format:	Book
Published:	Frontiers Media S.A., 2024-10-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Novel DNA Aptamers for Parkinson's Disease Treatment Inhibit α-Synuclein Aggregation and Facilitate its Degradation
by: Yuan Zheng, et al.
Published: (2018)

Exosomal DNA Aptamer Targeting α-Synuclein Aggregates Reduced Neuropathological Deficits in a Mouse Parkinson's Disease Model
by: Xiaoxi Ren, et al.
Published: (2019)

Plant Extracts and Phytochemicals Targeting α-Synuclein Aggregation in Parkinson's Disease Models
by: Hayate Javed, et al.
Published: (2019)

Recent advances in natural products targeting α-synuclein aggregation or clearance in Parkinson's disease
by: Jay Gupta, et al.
Published: (2023)

Rational design of small molecules able to inhibit α-synuclein amyloid aggregation for the treatment of Parkinson's disease
by: Serena Vittorio, et al.
Published: (2020)

Development of Small Molecules Targeting α-Synuclein Aggregation: A Promising Strategy to Treat Parkinson's Disease
by: Samuel Peña-Díaz, et al.
Published: (2023)

α‐Synuclein aggregation causes muscle atrophy through neuromuscular junction degeneration
by: Qiumei Yang, et al.
Published: (2023)

Neuronal Oxidative Stress Promotes α-Synuclein Aggregation In Vivo
by: Seok Joon Won, et al.
Published: (2022)

Suppression of abnormal α-synuclein expression by activation of BDNF transcription ameliorates Parkinson's disease-like pathology
by: Qianqian Cao, et al.
Published: (2022)

Mitochondrial dynamics in Parkinson's disease: a role for α-synuclein?
by: Victorio M. Pozo Devoto, et al.
Published: (2017)

Native α-Synuclein, 3-Nitrotyrosine Proteins, and Patterns of Nitro-α-Synuclein-Immunoreactive Inclusions in Saliva and Submandibulary Gland in Parkinson's Disease
by: Emilio Fernández-Espejo, et al.
Published: (2021)

PAMAM dendrimers of generation 4.5 loaded with curcumin interfere with α-synuclein aggregation
by: Daniela E. Igartúa, et al.
Published: (2023)

Alpha-Synuclein spreading in Parkinson disease
by: Ariadna eRecasens, et al.
Published: (2014)

Synthesis and Preliminary Characterization of Putative Anle138b-Centered PROTACs against α-Synuclein Aggregation
by: Martina Pedrini, et al.
Published: (2023)

LRRK2 Antisense Oligonucleotides Ameliorate α-Synuclein Inclusion Formation in a Parkinson's Disease Mouse Model
by: Hien Tran Zhao, et al.
Published: (2017)

LRRK2 Antisense Oligonucleotides Ameliorate α-Synuclein Inclusion Formation in a Parkinson's Disease Mouse Model
by: Hien Tran Zhao, et al.
Published: (2021)

LRRK2 Antisense Oligonucleotides Ameliorate α-Synuclein Inclusion Formation in a Parkinson's Disease Mouse Model
by: Hien Tran Zhao, et al.
Published: (2021)

A Matrigel-based 3D construct of SH-SY5Y cells models the α-synuclein pathologies of Parkinson's disease
by: Zhao-Feng Li, et al.
Published: (2022)

Multivalent design of the monoclonal SynO2 antibody improves binding strength to soluble α-Synuclein aggregates
by: Inga Petersen, et al.
Published: (2023)

Modeling Parkinson's Disease With the Alpha-Synuclein Protein
by: Mónica Gómez-Benito, et al.
Published: (2020)

Tricin promoted ATG-7 dependent autophagic degradation of α-synuclein and dopamine release for improving cognitive and motor deficits in Parkinson's disease
by: Xingxia Wang, et al.
Published: (2023)

Normalization of Overexpressed α-Synuclein Causing Parkinson's Disease By a Moderate Gene Silencing With RNA Interference
by: Masaki Takahashi, et al.
Published: (2015)

miRNA and antisense oligonucleotide-based α-synuclein targeting as disease-modifying therapeutics in Parkinson's disease
by: Vasanti Suvarna, et al.
Published: (2022)

α-Synuclein Toxicity in <i>Drosophila melanogaster</i> Is Enhanced by the Presence of Iron: Implications for Parkinson's Disease
by: Francesco Agostini, et al.
Published: (2023)

Rabphilin-3A as a novel target to reverse α-synuclein-induced synaptic loss in Parkinson's disease
by: Elena Ferrari, et al.
Published: (2022)

Polyethylenimine Nanoparticle-Mediated siRNA Delivery to Reduce α-Synuclein Expression in a Model of Parkinson's Disease
by: Christin Helmschrodt, et al.
Published: (2017)

GYY4137, an H2S Slow-Releasing Donor, Prevents Nitrative Stress and α-Synuclein Nitration in an MPTP Mouse Model of Parkinson's Disease
by: Xiaoou Hou, et al.
Published: (2017)

Blocking the FKBP12 induced dendrimeric burst in aberrant aggregation of α-synuclein by using the ElteN378 synthetic inhibitor
by: Gabriella Caminati, et al.
Published: (2019)

Quantitative systems pharmacology model of α‐synuclein pathology in Parkinson's disease‐like mouse for investigation of passive immunotherapy mechanisms
by: Olga Ivanova, et al.
Published: (2024)

Focused Ultrasound-Induced Blood-Brain Barrier Opening Enhanced α-Synuclein Expression in Mice for Modeling Parkinson's Disease
by: Chung-Yin Lin, et al.
Published: (2022)

Corynoxine B targets at HMGB1/2 to enhance autophagy for α-synuclein clearance in fly and rodent models of Parkinson's disease
by: Qi Zhu, et al.
Published: (2023)

Empagliflozin attenuates neurodegeneration through antioxidant, anti-inflammatory, and modulation of α-synuclein and Parkin levels in rotenone-induced Parkinson's disease in rats
by: Sanaa Ahmed, et al.
Published: (2022)

Environmental Enrichment Attenuates Oxidative Stress and Alters Detoxifying Enzymes in an A53T α-Synuclein Transgenic Mouse Model of Parkinson's Disease
by: Jung Hwa Seo, et al.
Published: (2020)

Functionalized lipid nanoparticles modulate the blood-brain barrier and eliminate α-synuclein to repair dopamine neurons
by: Xiaomei Wu, et al.
Published: (2024)

Hydroxytyrosol Decreases LPS- and α-Synuclein-Induced Microglial Activation In Vitro
by: Marta Gallardo-Fernández, et al.
Published: (2019)

Modelling α-synuclein processing in primary patient cells for pharmacological intervention
by: Jessica K. Smith, et al.
Published: (2023)

Axon degeneration and PGC-1α-mediated protection in a zebrafish model of α-synuclein toxicity
by: Kelley C. O'Donnell, et al.
Published: (2014)

Salidroside Promotes the Pathological α-Synuclein Clearance Through Ubiquitin-Proteasome System in SH-SY5Y Cells
by: Tao Li, et al.
Published: (2018)

Meta-analysis to implement alpha-synuclein in extracellular vesicles as a potential biomarker for parkinson's disease
by: Víctor H. Juárez-Vaquera, et al.
Published: (2023)

Synucleins Biochemistry and Role in Diseases
Published: (2020)